Q3 FY2026 · ended Sep 30, 2026 · Revenue $35.51M, +30.3% YoY · Filed Oct 27, 2026
Beta Bionics, Inc. (BBNX) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $35.5 million and a net loss of $24.4 million. Free cash flow was -$14.6 million. As of Sep 30, 2026 it held $373.6 million in cash and investments and $6.1 million in total debt.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- BBNX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Irvine, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1674632
- Former names
- Beta Bionics, Inc (until Jan 6, 2025)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $35.5M | $32.0M | $27.6M | $32.1M | $27.3M |
| Operating income | -$26.6M | -$25.6M | -$24.3M | -$16.1M | -$17.0M |
| Net income | -$24.4M | -$23.4M | -$21.9M | -$13.5M | -$14.2M |
| Diluted EPS | -$0.52 | -$0.53 | -$0.49 | -$0.30 | -$0.33 |
| Operating cash flow | -$12.3M | -$14.6M | -$23.8M | -$8.6M | -$8.7M |
| Free cash flow | -$14.6M | -$15.7M | -$25.2M | -$10.5M | -$10.0M |
| Total assets | $443.8M | $292.4M | $304.4M | $328.7M | $330.0M |
| Total liabilities | $42.4M | $36.0M | $33.2M | $41.1M | $35.3M |
| Stockholders' equity | $401.4M | $256.4M | $271.2M | $287.6M | $294.8M |
| Cash and investments | $373.6M | $225.1M | $239.4M | $264.6M | $274.0M |
| Total debt | $6.1M | $6.5M | $6.9M | $7.3M | $7.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 27, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 27, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Other events
|
Sep 17, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 15, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Jul 29, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 29, 2026 | Jul 29, 2026 |
All 285 Beta Bionics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.